Tzeng Stephany Y, Guarecuco Rohiverth, McHugh Kevin J, Rose Sviatlana, Rosenberg Evan M, Zeng Yingying, Langer Robert, Jaklenec Ana
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
J Control Release. 2016 Jul 10;233:101-13. doi: 10.1016/j.jconrel.2016.05.012. Epub 2016 May 11.
Vaccines are a critical clinical tool in preventing illness and death due to infectious diseases and are regularly administered to children and adults across the globe. In order to obtain full protection from many vaccines, an individual needs to receive multiple doses over the course of months. However, vaccine administration in developing countries is limited by the difficulty in consistently delivering a second or third dose, and some vaccines, including the inactivated polio vaccine (IPV), must be injected more than once for efficacy. In addition, IPV does not remain stable over time at elevated temperatures, such as those it would encounter over time in the body if it were to be injected as a single-administration vaccine. In this manuscript, we describe microspheres composed of poly(lactic-co-glycolic acid) (PLGA) that can encapsulate IPV along with stabilizing excipients and release immunogenic IPV over the course of several weeks. Additionally, pH-sensitive, cationic dopants such as Eudragit E polymer caused clinically relevant amounts of stable IPV release upon degradation of the PLGA matrix. Specifically, IPV was released in two separate bursts, mimicking the delivery of two boluses approximately one month apart. In one of our top formulations, 1.4, 1.1, and 1.2 doses of the IPV serotype 1, 2, and 3, respectively, were released within the first few days from 50mg of particles. During the delayed, second burst, 0.5, 0.8, and 0.6 doses of each serotype, respectively, were released; thus, 50mg of these particles released approximately two clinical doses spaced a month apart. Immunization of rats with the leading microsphere formulation showed more robust and long-lasting humoral immune response compared to a single bolus injection and was statistically non-inferior from two bolus injections spaced 1 month apart. By minimizing the number of administrations of a vaccine, such as IPV, this technology can serve as a tool to aid in the eradication of polio and other infectious diseases for the improvement of global health.
疫苗是预防因传染病导致疾病和死亡的关键临床工具,在全球范围内定期接种于儿童和成人。为了从许多疫苗中获得全面保护,个体需要在数月内接种多剂疫苗。然而,发展中国家的疫苗接种受到持续接种第二剂或第三剂困难的限制,并且一些疫苗,包括灭活脊髓灰质炎疫苗(IPV),必须多次注射才能产生效果。此外,IPV在高温下不会随时间保持稳定,例如如果作为单次给药疫苗注射到体内,它会随着时间在体内遇到的温度。在本手稿中,我们描述了由聚(乳酸-乙醇酸)(PLGA)组成的微球,其可以将IPV与稳定赋形剂一起封装,并在数周内释放具有免疫原性的IPV。此外,pH敏感的阳离子掺杂剂,如Eudragit E聚合物,在PLGA基质降解时会导致临床上相关量的稳定IPV释放。具体而言,IPV以两个单独的脉冲形式释放,模拟大约相隔一个月的两次推注给药。在我们的一种顶级配方中,分别从50mg颗粒中在头几天内释放出1.4、1.1和1.2剂IPV 1、2和3血清型。在延迟的第二次脉冲中,分别释放出每种血清型的0.5、0.8和0.6剂;因此,50mg这些颗粒释放出大约相隔一个月的两个临床剂量。用领先的微球配方免疫大鼠显示出与单次推注注射相比更强壮和持久的体液免疫反应,并且在统计学上不劣于相隔1个月的两次推注注射。通过最小化疫苗(如IPV)的给药次数,这项技术可以作为一种工具,有助于根除脊髓灰质炎和其他传染病,以改善全球健康。